CoChat

Harnessing Dietary Tryptophan: Bridging the Gap Between Neurobiology and Psychiatry in Depression Management

Open access
Chehadi, Amanda Chabrour, Pereira de Lima, Enzo, Detregiachi, Cláudia Rucco Penteado, Santos de Argollo Haber, Rafael, Catharin, Virgínia Maria Cavallari Strozze, Fornari Laurindo, Lucas, Engracia Valenti, Vitor, Machado Galhardi, Cristiano, Tanaka, Masaru, Maria Barbalho, Sandra · 2026 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 445 of the 458 references it cites were found in a registry or an index, and 13 are not checked yet.

Abstract

Major depressive disorder remains a leading cause of disability worldwide, with conventional antidepressants offering incomplete and often transient relief. Mounting evidence highlights disturbances in tryptophan (Trp) metabolism as a key biological axis linking inflammation, neuroplasticity, and mood regulation. Plant-derived compounds that modulate this pathway, including 5-hydroxytryptophan, isoflavones, berberine, and polyphenols, have emerged as promising candidates for integrative treatment strategies. Yet, despite encouraging preclinical and clinical findings, knowledge gaps persist regarding long-term efficacy, mechanistic specificity, and standardized therapeutic protocols. This narrative review explores how Trp modulators influence central and peripheral mechanisms relevant to depression, from serotonergic synthesis and kynurenine shunting to gut–brain–immune interactions. Evidence from animal models and randomized clinical trials is critically synthesized, with particular attention to outcomes on mood stabilization, anxiety reduction, cognitive function, and sleep regulation. Special emphasis is placed on translational potential, methodological limitations, and the need for harmonized research frameworks. Here we highlight that phytochemical interventions represent a mechanistically informed and biocompatible strategy for advancing depression management. By bridging neurobiology and clinical psychiatry, these insights may pave the way for next-generation therapeutics that integrate dietary, microbiota-targeted, and anti-inflammatory approaches. Broader application of this research could ultimately refine personalized psychiatry, expand therapeutic horizons, and contribute to global mental health resilience.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms27010465

Cites

445 of 458 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Integrated overview of major depressive disorder burden and plant-derived modulation of tryptophan pathways. This schematic summarizes the clinical burden of major depressive disorder (MDD) and highlights limitations of current selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT-norepinephrine reuptake inhibitor (SNRI) therapies, including delayed onset, sexual dysfunction, weight gain, hyponatremia, emotional blunting, and treatment resistance. Tryptophan metabolism is illustrated as a fork between the 5-HT pathway (promoting mood regulation and emotional balance) and the kynurenine (KYN) pathway (associated with inflammation, neurotoxicity, and melancholic features). Inflammatory cytokines such as interleukin (IL)-6 and interferon (IFN)-γ shift tryptophan away from 5-HT production by activating Indoleamine 2,3-dioxygenase (IDO), contributing to reduced 5-HT, anhedonia, low mood, and suicidality. Mechanistic points where plant-derived compounds may intervene are shown on the right, including enhancement of tryptophan hydroxylase (TPH) activity and 5-HT synthesis, inhibition of IDO1 activation to reduce neurotoxic KYN metabolites, and modulation of the gut microbiota to increase beneficial indoles and reduce inflammation. Collectively, these actions increase bioavailable tryptophan and 5-HTP, offering potential complementary strategies for improving depressive symptoms. Created using Mind the Graph (https://mindthegraph.com/, last accessed on 6 December 2025). Abbreviations: Trp, Tryptophan; 5-HTP, 5-Hydroxytryptophan; KYN, Kynurenine; QA, Quinolinic acid.
Figure 1 Integrated overview of major depressive disorder burden and plant-derived modulation of tryptophan pathways. This schematic summarizes the clinical burden of major depressive disorder (MDD) and highlights limitations of current selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT-norepinephrine reuptake inhibitor (SNRI) therapies, including delayed onset, sexual dysfunction, weight gain, hyponatremia, emotional blunting, and treatment resistance. Tryptophan metabolism is illustrated as a fork between the 5-HT pathway (promoting mood regulation and emotional balance) and the kynurenine (KYN) pathway (associated with inflammation, neurotoxicity, and melancholic features). Inflammatory cytokines such as interleukin (IL)-6 and interferon (IFN)-γ shift tryptophan away from 5-HT production by activating Indoleamine 2,3-dioxygenase (IDO), contributing to reduced 5-HT, anhedonia, low mood, and suicidality. Mechanistic points where plant-derived compounds may intervene are shown on the right, including enhancement of tryptophan hydroxylase (TPH) activity and 5-HT synthesis, inhibition of IDO1 activation to reduce neurotoxic KYN metabolites, and modulation of the gut microbiota to increase beneficial indoles and reduce inflammation. Collectively, these actions increase bioavailable tryptophan and 5-HTP, offering potential complementary strategies for improving depressive symptoms. Created using Mind the Graph (https://mindthegraph.com/, last accessed on 6 December 2025). Abbreviations: Trp, Tryptophan; 5-HTP, 5-Hydroxytryptophan; KYN, Kynurenine; QA, Quinolinic acid.CC BY · PubMed Central
Figure 2 Tryptophan (Trp) metabolism through the kynurenine (KYN) pathway: balancing neuroprotection and neurotoxicity in depression. This figure illustrates how immune-mediated activation of the KYN pathway disrupts Trp metabolism, linking inflammation with depression-related neuropathology. The stress hormone cortisol stimulates tryptophan 2,3-dioxygenase (TDO). Pro-inflammatory cytokines [interferon (IFN)-alpha (α), IFN-beta (β), IFN-gamma (γ), tumor necrosis factor alpha (TNF-α)] and lipopolysaccharide (LPS) induce indoleamine 2,3-dioxygenases (IDOs), diverting Trp away from serotonin (5-HT) synthesis toward KYN production. In contrast, anti-inflammatory cytokines [interleukin (IL)-4, IL-10] and superoxide dismutase (SOD) counteract this process. Oxygen molecule (O2), IFN-β, IFN-γ, and TNF-α stimulate and IL-4, IL-10, and SOD suppress kynurenine 3-monooxygenase (KMO). Furthermore, IDOs, TDO, and KMO activities are influenced by positive and negative feedback loops. Peripheral KYN crosses the blood–brain barrier, where it undergoes two competing fates: (i) conversion into kynurenic acid (KYNA), a putative neuroprotective N-Methyl-D-Aspartate (NMDA) receptor antagonist with putative antioxidant properties, or (ii) metabolism into 3-hydroxykynurenine (3-HK) and quinolinic acid (QA), which promotes reactive oxygen species (ROS), NMDA receptor overstimulation, mitochondrial dysfunction, and neuronal apoptosis, ultimately leading to neurodegeneration. The dashed inhibitory arrow indicates that enhanced KYN metabolism reduces 5-HT and melatonin synthesis, impairing neurotransmission and neuroprotection. The balance between KYNA and QA determines whether the KYN pathway promotes resilience or vulnerability to depression. Abbreviations: ↑, Increase.
Figure 2 Tryptophan (Trp) metabolism through the kynurenine (KYN) pathway: balancing neuroprotection and neurotoxicity in depression. This figure illustrates how immune-mediated activation of the KYN pathway disrupts Trp metabolism, linking inflammation with depression-related neuropathology. The stress hormone cortisol stimulates tryptophan 2,3-dioxygenase (TDO). Pro-inflammatory cytokines [interferon (IFN)-alpha (α), IFN-beta (β), IFN-gamma (γ), tumor necrosis factor alpha (TNF-α)] and lipopolysaccharide (LPS) induce indoleamine 2,3-dioxygenases (IDOs), diverting Trp away from serotonin (5-HT) synthesis toward KYN production. In contrast, anti-inflammatory cytokines [interleukin (IL)-4, IL-10] and superoxide dismutase (SOD) counteract this process. Oxygen molecule (O2), IFN-β, IFN-γ, and TNF-α stimulate and IL-4, IL-10, and SOD suppress kynurenine 3-monooxygenase (KMO). Furthermore, IDOs, TDO, and KMO activities are influenced by positive and negative feedback loops. Peripheral KYN crosses the blood–brain barrier, where it undergoes two competing fates: (i) conversion into kynurenic acid (KYNA), a putative neuroprotective N-Methyl-D-Aspartate (NMDA) receptor antagonist with putative antioxidant properties, or (ii) metabolism into 3-hydroxykynurenine (3-HK) and quinolinic acid (QA), which promotes reactive oxygen species (ROS), NMDA receptor overstimulation, mitochondrial dysfunction, and neuronal apoptosis, ultimately leading to neurodegeneration. The dashed inhibitory arrow indicates that enhanced KYN metabolism reduces 5-HT and melatonin synthesis, impairing neurotransmission and neuroprotection. The balance between KYNA and QA determines whether the KYN pathway promotes resilience or vulnerability to depression. Abbreviations: ↑, Increase.CC BY · PubMed Central
Figure 3 The light–suprachiasmatic nucleus (SCN)–pineal pathway regulating melatonin biosynthesis. Light information from the retina reaches the suprachiasmatic nucleus (SCN), the master circadian pacemaker, via the retinohypothalamic tract. The SCN projects to the paraventricular nucleus and modulates sympathetic innervation of the pineal gland. In darkness, SCN activity stimulates pineal metabolism of Trp through a sequential enzymatic cascade: tryptophan hydroxylase (TPH) converts Trp into 5-hydroxytryptophan (5-HTP), aromatic L-amino acid decarboxylase (AADC) generates serotonin (5-HT), serotonin N-acetyltransferase (SNAT) produces N-acetylserotonin, and acetylserotonin O-methyltransferase (ASMT) catalyzes the final step to melatonin. Light exposure suppresses this pathway, reducing melatonin output. Melatonin acts as a key circadian regulator, influencing sleep, neuroendocrine rhythms, and mood regulation. Abbreviations: ↓, Decrease.
Figure 3 The light–suprachiasmatic nucleus (SCN)–pineal pathway regulating melatonin biosynthesis. Light information from the retina reaches the suprachiasmatic nucleus (SCN), the master circadian pacemaker, via the retinohypothalamic tract. The SCN projects to the paraventricular nucleus and modulates sympathetic innervation of the pineal gland. In darkness, SCN activity stimulates pineal metabolism of Trp through a sequential enzymatic cascade: tryptophan hydroxylase (TPH) converts Trp into 5-hydroxytryptophan (5-HTP), aromatic L-amino acid decarboxylase (AADC) generates serotonin (5-HT), serotonin N-acetyltransferase (SNAT) produces N-acetylserotonin, and acetylserotonin O-methyltransferase (ASMT) catalyzes the final step to melatonin. Light exposure suppresses this pathway, reducing melatonin output. Melatonin acts as a key circadian regulator, influencing sleep, neuroendocrine rhythms, and mood regulation. Abbreviations: ↓, Decrease.CC BY · PubMed Central
Figure 4 Dietary tryptophan (Trp) metabolism by gut microbiota and its systemic effects. Exogenous dietary Trp, derived from protein-rich foods, is metabolized by intestinal microbiota into indole derivatives, including indole-3-aldehyde (IAld), indole-3-acetic acid (IAA), indole-3-propionic acid (IPA), and indoleacrylic acid. These metabolites enter the systemic circulation and exert pleiotropic effects on host physiology. IAld activates the aryl hydrocarbon receptor (AhR), modulating mucosal immunity, while IPA provides neuroprotection through antioxidant activity. IAA regulates intestinal motility and epithelial function, whereas indoleacrylic acid strengthens gut barrier integrity. Collectively, these microbial metabolites influence brain activity (neurotransmission, neuroinflammation, mood), bowel function (motility, barrier homeostasis), and the immune system (immune tolerance, inflammation). This highlights the central role of gut microbiota–Trp metabolism in the gut–brain–immune axis.
Figure 4 Dietary tryptophan (Trp) metabolism by gut microbiota and its systemic effects. Exogenous dietary Trp, derived from protein-rich foods, is metabolized by intestinal microbiota into indole derivatives, including indole-3-aldehyde (IAld), indole-3-acetic acid (IAA), indole-3-propionic acid (IPA), and indoleacrylic acid. These metabolites enter the systemic circulation and exert pleiotropic effects on host physiology. IAld activates the aryl hydrocarbon receptor (AhR), modulating mucosal immunity, while IPA provides neuroprotection through antioxidant activity. IAA regulates intestinal motility and epithelial function, whereas indoleacrylic acid strengthens gut barrier integrity. Collectively, these microbial metabolites influence brain activity (neurotransmission, neuroinflammation, mood), bowel function (motility, barrier homeostasis), and the immune system (immune tolerance, inflammation). This highlights the central role of gut microbiota–Trp metabolism in the gut–brain–immune axis.CC BY · PubMed Central
Figure 5 Tryptophan (Trp)–indole metabolism and its pathological consequences. Gut microbiota such as Escherichia coli and Bacteroides spp. metabolize dietary Trp via tryptophanase into indole. Host and environmental factors (genetics, diet, stress, aging, physical activity) modulate this pathway. Dysregulated Trp metabolism reduces serotonin (5-HT) availability, impairing enteric nervous system (ENS) signaling, metabolism, glucose absorption, and intestinal motility, contributing to chronic gastrointestinal disorders such as ulcerative colitis. Indole derivatives, particularly indoxyl sulfate (IS), accumulate when excretion is impaired, leading to systemic inflammation, oxidative stress, and cellular damage in the colon and liver. Overexpression of indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase 2 (TDO2) further links altered Trp metabolism to carcinogenic processes in the brain, breast, and lungs. This highlights the central role of Trp–indole metabolism in the gut–brain–immune axis, cancer progression, and systemic disease.
Figure 5 Tryptophan (Trp)–indole metabolism and its pathological consequences. Gut microbiota such as Escherichia coli and Bacteroides spp. metabolize dietary Trp via tryptophanase into indole. Host and environmental factors (genetics, diet, stress, aging, physical activity) modulate this pathway. Dysregulated Trp metabolism reduces serotonin (5-HT) availability, impairing enteric nervous system (ENS) signaling, metabolism, glucose absorption, and intestinal motility, contributing to chronic gastrointestinal disorders such as ulcerative colitis. Indole derivatives, particularly indoxyl sulfate (IS), accumulate when excretion is impaired, leading to systemic inflammation, oxidative stress, and cellular damage in the colon and liver. Overexpression of indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase 2 (TDO2) further links altered Trp metabolism to carcinogenic processes in the brain, breast, and lungs. This highlights the central role of Trp–indole metabolism in the gut–brain–immune axis, cancer progression, and systemic disease.CC BY · PubMed Central
Figure 6 Dual pathways of tryptophan (Trp) metabolism and their neuropsychiatric implications. Trp crosses the blood–brain barrier (BBB) via LAT1 transporters and follows two competing metabolic routes. One route converts Trp to serotonin (5-HT) through tryptophan hydroxylase (TPH), which subsequently gives rise to melatonin, regulating circadian rhythms and mood. Impaired 5-HT synthesis contributes to depression and sleep disturbances. Alternatively, Trp is metabolized through the kynurenine (KYN) pathway, primarily via indoleamine 2,3-dioxygenase (IDO). This generates metabolites with opposing actions: quinolinic acid (QA), a neurotoxic N-Methyl-D-Aspartate (NMDA) receptor agonist that promotes excitotoxicity, oxidative stress, and cognitive dysfunction, and kynurenic acid (KYNA), a neuroprotective NMDA receptor antagonist that counterbalances QA’s toxicity. Dysregulation of the Trp–5-HT–KYN axis disrupts neurotransmission, neuroprotection, and circadian control, ultimately contributing to depression, memory problems, and neurodegeneration.
Figure 6 Dual pathways of tryptophan (Trp) metabolism and their neuropsychiatric implications. Trp crosses the blood–brain barrier (BBB) via LAT1 transporters and follows two competing metabolic routes. One route converts Trp to serotonin (5-HT) through tryptophan hydroxylase (TPH), which subsequently gives rise to melatonin, regulating circadian rhythms and mood. Impaired 5-HT synthesis contributes to depression and sleep disturbances. Alternatively, Trp is metabolized through the kynurenine (KYN) pathway, primarily via indoleamine 2,3-dioxygenase (IDO). This generates metabolites with opposing actions: quinolinic acid (QA), a neurotoxic N-Methyl-D-Aspartate (NMDA) receptor agonist that promotes excitotoxicity, oxidative stress, and cognitive dysfunction, and kynurenic acid (KYNA), a neuroprotective NMDA receptor antagonist that counterbalances QA’s toxicity. Dysregulation of the Trp–5-HT–KYN axis disrupts neurotransmission, neuroprotection, and circadian control, ultimately contributing to depression, memory problems, and neurodegeneration.CC BY · PubMed Central
Figure 7 Mechanistic actions of phytochemicals in depression. Phytochemicals, including 5-hydroxytryptophan (5-HTP), isoflavones, berberine, and polyphenols, exert central effects through modulation of the gut microbiome (via tryptophan [Trp] metabolism), regulation of immune signaling (attenuation of inflammation), and stimulation of neurogenesis (enhancement of plasticity and mood stabilization), collectively contributing to antidepressant outcomes.
Figure 7 Mechanistic actions of phytochemicals in depression. Phytochemicals, including 5-hydroxytryptophan (5-HTP), isoflavones, berberine, and polyphenols, exert central effects through modulation of the gut microbiome (via tryptophan [Trp] metabolism), regulation of immune signaling (attenuation of inflammation), and stimulation of neurogenesis (enhancement of plasticity and mood stabilization), collectively contributing to antidepressant outcomes.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. Ribas, 2021, The different roles of Griffonia simplicifolia in the treatment of depression: A narrative review, Int. J. Complement. Alt. Med., 14, 167
  2. Moosavi, 2016, Modulation of neurotrophic signaling pathways by polyphenols, Drug Des. Devel Ther., 10, 23

Cited by

See all 12

Metadata

Authors
Chehadi, A. C., Pereira de Lima, E., Detregiachi, C. R. P., Santos de Argollo Haber, R., Catharin, V. M. C. S., Fornari Laurindo, L., Engracia Valenti, V., Machado Galhardi, C., Tanaka, M., & Maria Barbalho, S.
Affiliations
  • Universidade de Marília (BR)
  • Department of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, SP, Brazil
  • Graduate Program in Structural and Functional Interactions in Rehabilitation, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, SP, Brazil
  • Division of Cellular Growth, Hemodynamic and Homeostasis Disorders, Graduate Program in Medical Sciences, Faculdade de Medicina, Universidade de São Paulo (USP), São Paulo 01246-903, SP, Brazil
  • Department of Cardiovascular and Metabolic Health, School of Philosophy and Sciences, Universidade Estadual Paulista (UNESP), Marília 17525-900, SP, Brazil
  • University of Szeged (HU)
Corresponding author
Tanaka, Masaru
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2026-01-01
Volume
27
Issue
1
Pages
465
ISSN
1422-0067 (ISSN-L)
OpenAlex
W7118002548
Cited by
8
References
431
Citations by year
2026: 8
FWCI
5.26
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Funders
HUN-REN Hungarian Research Network
Topics
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
Keywords
tryptophan metabolism, major depressive disorder, 5-hydroxytryptophan, isoflavones, berberine, polyphenols, phytochemicals, kynurenine pathway, gut-brain-immune axis, inflammation, neuroplasticity, anxiety, sleep regulation, cognitive function, precision psychiatry, dietary intervention
MeSH terms
Animals, Antidepressive Agents, Depression, Major Depressive Disorder, Depressive Disorder, Major, Diet, Humans, Neurobiology, Tryptophan

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.